| P2093 | author name string | Suzanne M de la Monte | |
| | Ming Tong | |
| | Chetram Deochand | |
| | John Didsbury | |
| P2860 | cites work | Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease | Q27021700 |
| | Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation | Q28156047 |
| | Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease | Q28259585 |
| | Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling | Q28574687 |
| | Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? | Q29619535 |
| | Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status | Q30471693 |
| | Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease | Q30479198 |
| | Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. | Q30984127 |
| | The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. | Q33766911 |
| | Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages | Q33870766 |
| | Alzheimer's disease is type 3 diabetes-evidence reviewed | Q34020000 |
| | Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. | Q34400472 |
| | Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine | Q34474707 |
| | Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. | Q34609941 |
| | Insulin resistance and Alzheimer's disease: molecular links & clinical implications. | Q34657393 |
| | Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? | Q34669518 |
| | Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study | Q35123326 |
| | Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors | Q35127251 |
| | Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle | Q35178615 |
| | FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? | Q35792038 |
| | Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes | Q35794263 |
| | Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline | Q35858095 |
| | Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease | Q35997866 |
| | Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease | Q36044265 |
| | Insulin resistance and Alzheimer's disease | Q36143429 |
| | Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation | Q36305066 |
| | Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease | Q36599797 |
| | Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications | Q36667507 |
| | Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment | Q36789901 |
| | Molecular connexions between dementia and diabetes. | Q36837972 |
| | Role for neuronal insulin resistance in neurodegenerative diseases | Q36853917 |
| | Common pathological processes in Alzheimer disease and type 2 diabetes: a review | Q36963272 |
| | Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach | Q36993189 |
| | Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. | Q37094666 |
| | Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta} | Q37253971 |
| | Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease | Q37332266 |
| | Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes | Q37599904 |
| | Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells | Q37736265 |
| | How does diabetes accelerate Alzheimer disease pathology? | Q37788954 |
| | Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. | Q37845040 |
| | Insulin resistance and pathological brain ageing | Q37942690 |
| | Higher glucose levels associated with lower memory and reduced hippocampal microstructure | Q39327291 |
| | Insulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. | Q39533821 |
| | Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes | Q39600965 |
| | Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro | Q39648939 |
| | A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease | Q39782076 |
| | Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin | Q40722638 |
| | The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation | Q41024985 |
| | Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. | Q41841220 |
| | Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury | Q42163881 |
| | Monocrotophos induced oxidative damage associates with severe acetylcholinesterase inhibition in rat brain | Q42721928 |
| | Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study | Q42925710 |
| | Cholinergic dysfunctions and enhanced oxidative stress in the neurobehavioral toxicity of lambda-cyhalothrin in developing rats | Q44440602 |
| | Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. | Q44516272 |
| | Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome | Q45865881 |
| | Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology | Q46386533 |
| | Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. | Q48179140 |
| | Stereotaxic gene delivery in the rodent brain | Q48218703 |
| | Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type | Q48292484 |
| | Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis | Q48404189 |
| | Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. | Q48575219 |
| | Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). | Q48883784 |
| | IRS-2 branch of IGF-1 receptor signaling is essential for appropriate timing of myelination | Q48958568 |
| | Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. | Q53196303 |
| | Glycolytic enzymes from human autoptic brain cortex: Normal aged and demented cases | Q53196953 |
| | Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? | Q56049682 |
| | Amyloid beta oligomers induce impairment of neuronal insulin receptors | Q80846857 |
| | Invivo insulin deficiency as a potential etiology for demyelinating disease | Q81628985 |
| | The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells | Q83011317 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 123-138 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease | |
| P478 | volume | 51 | |